CorePlus, Puerto Rico’s fully digital precision pathology and clinical laboratory, announced today the integration of the ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Human tissue is intricate, complex and, of course, three dimensional. But the thin slices of tissue that pathologists most often use to diagnose disease are two dimensional, offering only a limited ...

A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...

Scientists at @HopkinsMedicine say they found a class of inhibitors that may lead to better, more effective treatments for ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Researchers have developed a fully human antibody that suppressed tumor growth and metastatic spread in preclinical models of ...

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men. About half of prostate ...

Significant progress in localized prostate cancer has been made, including improved and early detection, targeted biopsy, grading, disease prognostication, and outcome prediction, using imaging and ...

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

According to the institute, a single, reliable test to differentiate aggressive, life-threatening cancers from slower-growing ...